You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Minimally Invasive Cardiac Monitor for Neonatal and Pediatric ICU

    SBC: TRANSONIC SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Currently there exists no technology for routine measurement of cardiac output (CO) in neonates (0.4-2.5Kg) and low weight pediatric (2.5Kg+) patients in the intensive care unit (ICU). Accurate measurement of CO would a llow for better assessment of therapies and thereby improve patient health care. Conventional methods used with adults for routine CO measureme ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia

    SBC: INTRA-CELLULAR THERAPIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal is submitted as a Phase II SBIR application, pursuant to our existing Phase I grant, which was funded in response to the NIMH Program Announcement #PA-02-027 entitled: "Pharmacological agents and drugs for mental disorders". The development of new pharmaceuticals for neuropsychiatric disorders is limited by the lack of rapid and effective methods ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Refanalin for lung preservation and transplantation

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Lung transplantation is the only effective treatment modality for patients with end-stage lung disease. Ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of the lung is a major immu ne-independent factor adversely affecting early graft function, graft viability and recipient morbidity and mortality. Marginal donor lungs, ar ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Educational Television Program for Children of Immigrant Families

    SBC: Transcendent International, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The language barrier between immigrant parents and their English-dominant children is a pervasive and relatively unrecognized problem in an estimated 12 million U.S. households. This intergenerational language gap often leads to adverse health outcomes for both children and adults for the following reasons: (1) it hinders young children's ability to communicat ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Nitrogen Enriched Air for Fire Suppression

    SBC: COMPACT MEMBRANE SYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this Compact Membrane Systems (CMS) program is to develop a new platform technology for fire suppression and fire prevention systems around membrane supplied nitrogen enriched air (NEA). The limitation that the atmospheres used in the fire suppression be breathable to occupants in the proximity of a fire is easily accomplished by CMS technolog ...

    SBIR Phase II 2008 Department of Health and Human ServicesCenters for Disease Control and Prevention
  6. Ultrasound-Mediated Blood-Brain Barrier Permeabilization in Primates

    SBC: Virscio Inc            Topic: N/A

    DESCRIPTION (provided by applicant): The blood-brain barrier (BBB) represents both a safeguard against the penetration of physiologically harmful substances into the central nervous system (CNS), as well as a considerable hurdle to the delivery of therapeu tic agents. A technology allowing safe, targeted, reversible opening of the BBB would potentially revolutionize both the study and treatment of ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  7. High Throughput in Vivo Drug Discovery- Phase II

    SBC: PGI HOLDING CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): This Phase II application is being submitted in response to a continuing NIMH program announcement for Pharmacological Agents and Drugs for Mental Disorders. The goal of the proposal is to use an innovative behavior-dri ven approach to psychiatric drug discovery to overcome the major limitations associated with target-driven approaches that have impeded the dis ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Treatment of Surgical Sepsis with AM/AMBP-1

    SBC: THERASOURCE, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): This SBIR Phase II proposal is a plan to further develop a new therapeutic approach that will save the lives of patients with sepsis (especially surgical sepsis), a condition that affects 750,000 people every year in th e United States alone and also causes high mortality worldwide. Although activated protein C [APC, Drotrecogin alpha (activated), Xigris. marke ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Transgenic Rabbit Model for Cardiovascular Disease

    SBC: EVERGEN BIOTECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cardiovascular disease (CVD) is the single most common cause of death in the United States. Although the study of the CVD has greatly benefited from the use of gene-targeted transgenic mouse models, these small rodents do not accurately reflect human cardiovascular physiology. The Rabbit would be an excellent animal model for CVD research, considering its many ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. Hypothermic Storage and Cryopreservation of Corneas

    SBC: CELL PRESERVATION SERVICES INC            Topic: N/A

    DESCRIPTION (provided by applicant): Cell Preservation Services, Inc. (CPSI) is a biotechnology company dedicated to the development of novel technologies in the area of low temperature biology and medicine. CPSI's core molecular strategy is focused on und erstanding and manipulating the cell survival and cell death pathways that appear to be cell-specific and are activated as a consequence of low ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government